Watch on earnings: Monthly cash burn rate and quarters of runway remaining (critical survival metric), FDA communication timelines and regulatory submission status updates, Clinical trial patient enrollment rates and data readout schedules.
One Sentence Summary:
HeartSciences: the story is balanced — fda regulatory milestones: 510(k) clearance or de novo pathway approval decisions for myovista platform.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
